

MPAC meeting 11- 13 September 2013

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Eleven members reported relevant interests, which are disclosed below. It was concluded that all members could take part in full in all of the discussions, except for one member who will be recused from the session on “durability of LLINs” where they have a conflict of interest.

All the reported relevant interests are summarized below:

Salim Abdulla

Is director of the Ifakara Health Institute, which receives research funding from MVI. This interest was assessed as non-personal, non-specific and financially significant*.

Patricia Graves

Receives research support in the form of ASAQ donations from Sanofi Aventis. This interest was assessed as non-personal, non-specific and financially significant*.

Brian Greenwood

Receives research funding from the Malaria Vaccine Initiative for the RTS,S vaccine trial. This interest was assessed as non-personal, non-specific, and financially significant*.

Rose Leke

Receives funding from Pfizer as a consultant. This interest was assessed as personal, non-specific and not financially significant*. She also receives research funding from the National Institute of Allergy and Infectious Diseases (NIAID), USA. This interest was assessed as non-personal, non-specific and financially significant*.

Kevin Marsh

Is on the scientific advisory board for the Novartis Vaccine Institute for Global Health. This interest was assessed as non-personal, non-specific, and financially significant*.

Sylvia Meek

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, AusAID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant*.

Allan Schapira

Received consultancy fees from GHTech, the Bill & Melinda Gates Foundation, World Bank, UNDP, and the Swiss Tropical and Public Health Institute. This interest was assessed as being personal, non-specific, and financially significant*.

Laurence Slutsker

Receives research support from MVI. This interest was assessed as personal, non-specific and not financially significant*.

Marcel Tanner

Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, MMV, Wellcome Trust,

Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, non-specific, and financial significant*.

Neena Valecha

Directs the National Institute of Malaria Research - New Delhi, which receives research funding from companies: BASF, Sumitomo, Vestergaard, Bayer, and Syngenta. This interest was assessed to be non-personal, specific and financially significant*. Dr. Valecha will be recused from the session on the durability of LLINs, and will have no involvement in decision-making related to guidance on LLIN durability.

Nick White

Receives research funding from MMV, Novartis, Holley-Cotec and GSK. This interest was assessed to be non-personal, non-specific, and financially significant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".

Last updated: 10 September 2013